PharmaNutra S.p.A. · MIL:PHN
PharmaNutra — Q1 2023 Earnings Presentation
22 slides from PharmaNutra's earnings presentation, May 8, 2023
Slide 1: Q1 2023 Financial Results
Q1_2023 FINANCIAL RESULTS May 8th, 2023
Slide 2: Disclaimer
2 DISCLAIMER This document has been prepared by Pharmanutra S.p.A. (the “Company”) for use during meetings with investors and financial analyst and is solely for information purposes. It contains solely data and information provided by the Company or already in the public domain. This Document may n
Slide 3: Group Presentation & Highlights 2022
GROUP PRESENTATION & HIGHLIGHTS 2022
Slide 4: Pharmanutra Group
4 PHARMANUTRA 2022 GROUP Research and development of bioimpedance medical devices and software for body composition analysis PharmaNutra holds 100% of 2010 Junia Pharma and Alesco and at the end of the year completed Medical products and devices, OTC and dietary the acquisition of 100% of the supple
Slide 5: Highlights Q1 2023
5 HIGHLIGHTS Q1 2023 ▪ Launch of the new line of products dedicated to sports nutrition: Cetilar® Nutrition, a truly innovative line of products developed thanks to the application of Sucrosomial® Technology. ▪ Set up of Pharmanutra España ▪ Historical record of monthly units sold on the Italian mar
Slide 6: Economic and Financial Data
6 ECONOMIC AND FINANCIAL DATA
Slide 7: Highlights Q1 2023
7 HIGHLIGHTS Q1 2023 + 25% NET REVENUES € 23,6 M (+25,3% COMPARE TO Q1 2022) ▪ 25,3% Increase in Net Sales Revenues EBITDA Adjusted € 6,6 M + 25%* (27,7% MARGIN ON REVENUES) ▪ 25%* EBITDA Adjusted Growth * excl. 2023 non recurring items ▪ 27,7% EBITDA Adjusted Margin on Revenues ▪ 33%* Net Result ex
Slide 8: Highlights Comparison Excluding Akern
8 HIGHLIGHTS COMPARISON EXCLUDING AKERN 2023 excl. 2023 Total AKN Amounts (€/000) 2022 ∆ 23/22 ∆ 23/22 2023 AKN Akern Group Contribution Net Sales Revenues 22.073 18.840 17,2% 23.608 25,3% 1.535 8,1% EBITDA 6.692 5.264 27,1% 7.378 40,2% 686 13,0% Net Result 4.975 3.486 42,7% 5.431 55,8% 456 13,1% Ne
Slide 9: Net Revenues
9 NET REVENUES Net revenues at 31.03.2023 accounted for € 23.6 million, recording a growth of 25,3% compared to the previous year. Revenues on domestic market grew by 27,1% while revenues on the foreign market recorded a growth of 21,2%. Akern’s net revenues accounted for € 1,5 million, about 6,5% o
Slide 10: Profit and Loss
10 PROFIT AND LOSS PHN GROUP PROFIT AND LOSS (€/000) 31/03/2023 Management 31/03/2023 31/03/2022 REVENUES Adjustments Adjusted Consolidated revenues accounted for € 23,6 million with an increase of A) REVENUES 24.575 (797) 23.778 18.967 25% compared to the same period of the previous year. The incre
Slide 11: Reclassified Consolidated Balance Sheet
11 RECLASSIFIED CONSOLIDATED BALANCE SHEET Amounts in €/000 31/03/2023 31/12/2022 ∆ 2022 vs 2021 Operating Working Capital Trade receivables 24.156 21.647 2.509 The increase in trade receivables is due to higher revenues. Inventories 7.419 5.261 2.158 The increase in inventories refers to the implem
Slide 12: Consolidated Cash Flow
12 CONSOLIDATED CASH FLOW Cash Flow (€/000) 31/03/2023 31/03/2022 Net Result 5.431 3.486 CASH FROM OPERATING ACTIVITIES NON MONETARY EXPENSES Change in operating working capital Amortization, depreciation and w.o. 411 291 Increase in trade receivables due to higher revenues and sales volumes. Accrua
Slide 13: Net Financial Position
13 NET FINANCIAL POSITION NFP The Net Financial Position at 31.03.2023 accounted for € 2,9 million. The decrease compared to 31.12.2022 is mainly due to capital expenditures related to the construction of the new Headquarter and other operating capex (€ 3,7 million), to the purchases of treasury sha
Slide 14: Market
MARKET
Slide 15: Trend IMS & OD
15 Trend IMS & OD Quarterly Average Source IQVIA
Slide 16: Iron Supplements SiderAL Market Share in Italy
16 IRON SUPPLEMENTS SIDERAL® MARKET SHARE IN ITALY Excluding products that contain only lactoferrin Source IQVIA
Slide 17: Anti-Inflammatory Topical Cream Cetilar Market Share in Italy
17 ANTI-INFLAMMATORY TOPICAL CREAM CETILAR® MARKET SHARE IN ITALY Source IQVIA Source IQVIA
Slide 18: Apportal compared to the reference markets
18 APPORTAL® COMPARED TO THE REFERENCE MARKETS
Slide 19: International Development
19 INTERNATIONAL DEVELOPMENT New distribution contracts signed: Indonesia, Kuwait, Mexico, Benelux, Chile, Uruguay, Guatemala, Panama, El Salvador, Costa Rica. COUNTRIES PARTNERS Contracts 71 44 Active Sales 54 37 On-going Registration 17 7 On-going Negotiation 11 11
Slide 20: Outlook 2023
OUTLOOK 2023 @PHARMANUTRA ea aia
Slide 21: Outlook 2023
21 OUTLOOK 2023 ▪ The Group's existing business foresees a high double-digit organic growth trend in terms of revenues and margins. Revenues on the domestic market are estimated to increase with a growth in line with 2022 (+20%). The Group marginality on revenues will be slightly affected by the imp
Slide 22: Pharmanutra
MPHARMANUTRA ogee samara